Xiangli Jiang

663 total citations
23 papers, 512 citations indexed

About

Xiangli Jiang is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Xiangli Jiang has authored 23 papers receiving a total of 512 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 12 papers in Oncology and 9 papers in Cancer Research. Recurrent topics in Xiangli Jiang's work include Lung Cancer Research Studies (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Xiangli Jiang is often cited by papers focused on Lung Cancer Research Studies (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Xiangli Jiang collaborates with scholars based in China, United States and Germany. Xiangli Jiang's co-authors include Xiubao Ren, Qian Sun, Hui Li, Kai Li, Zhongli Zhan, Dingzhi Huang, Chun Huang, Jingya Wang, Xia Wang and Zhiqiang Wu and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Xiangli Jiang

21 papers receiving 508 citations

Peers

Xiangli Jiang
Yang Peng China
Jason Kirk United States
Mingyi Ju China
Yongfeng Wu China
Shunli Peng China
Tzu‐Hua Chang Taiwan
Wenkai Zhu China
Rui Gou China
Yang Peng China
Xiangli Jiang
Citations per year, relative to Xiangli Jiang Xiangli Jiang (= 1×) peers Yang Peng

Countries citing papers authored by Xiangli Jiang

Since Specialization
Citations

This map shows the geographic impact of Xiangli Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiangli Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiangli Jiang more than expected).

Fields of papers citing papers by Xiangli Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiangli Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiangli Jiang. The network helps show where Xiangli Jiang may publish in the future.

Co-authorship network of co-authors of Xiangli Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Xiangli Jiang. A scholar is included among the top collaborators of Xiangli Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiangli Jiang. Xiangli Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sun, Yanchen, Jing Wang, Maobin Meng, et al.. (2024). MicroRNA-384 radiosensitizes human non-small cell lung cancer by impairing DNA damage response and repair signaling, which is inhibited by NF-κB. Cancer Biology and Medicine. 21(11). 1–17.
2.
Jiang, Xiangli, Esther A. Zaal, Celia R. Berkers, et al.. (2024). P53-dependent hypusination of eIF5A affects mitochondrial translation and senescence immune surveillance. Nature Communications. 15(1). 7458–7458. 6 indexed citations
3.
4.
Jiang, Xiangli, et al.. (2022). Roles of eIF5A in the immunosurveillance of cellular senescence. Cancer Biology and Medicine. 19(11). 1–5. 2 indexed citations
5.
He, Xiaoning, Jing Wu, Song Xu, et al.. (2021). Differences in Lung Cancer Treatment Preferences Among Oncologists, Patients and Family Members: A Semi-Structured Qualitative Study in China. Patient Preference and Adherence. Volume 15. 775–783. 6 indexed citations
6.
Wang, Jingya, Tao Sun, Zhaoting Meng, et al.. (2021). XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a. Cancer Letters. 503. 197–212. 33 indexed citations
7.
Wang, Xin, Zeyun Mi, Xiangli Jiang, et al.. (2021). STAT3/miR-135b/NF-κB axis confers aggressiveness and unfavorable prognosis in non-small-cell lung cancer. Cell Death and Disease. 12(5). 493–493. 45 indexed citations
8.
Wang, Qingsong, Gang Wang, Lei Chen, et al.. (2020). Prognostic and clinicopathological significance of NRF2 expression in non-small cell lung cancer: A meta-analysis. PLoS ONE. 15(11). e0241241–e0241241. 15 indexed citations
9.
Wu, Zhiqiang, Zhuang Liu, Xiangli Jiang, et al.. (2019). Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits. Journal of Experimental & Clinical Cancer Research. 38(1). 341–341. 19 indexed citations
10.
Wu, Zhiqiang, Zeyun Mi, Maobin Meng, et al.. (2019). WT1‐interacting protein inhibits cell proliferation and tumorigenicity in non‐small‐cell lung cancer via the AKT/FOXO1 axis. Molecular Oncology. 13(5). 1059–1074. 18 indexed citations
11.
Sun, Qian, Yanan Wang, Haiyong Peng, et al.. (2018). Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis. Cell Death and Differentiation. 25(6). 1160–1173. 58 indexed citations
12.
13.
Wang, Jingya, Yue Zhang, Shaohua Ge, et al.. (2018). Exosomal miR-27a Derived from Gastric Cancer Cells Regulates the Transformation of Fibroblasts into Cancer-Associated Fibroblasts. Cellular Physiology and Biochemistry. 49(3). 869–883. 103 indexed citations
14.
Liu, Zhujun, Jing Wang, Zhaoting Meng, et al.. (2018). CD31‐labeled circulating endothelial cells as predictor in anlotinib‐treated non‐small‐cell lung cancer: Analysis on ALTER‐0303 study. Cancer Medicine. 7(7). 3011–3021. 23 indexed citations
15.
Jiang, Xiangli, et al.. (2017). Worse disease-free, tumor-specific, and overall survival in surgically-resected lung adenocarcinoma patients with ALK rearrangement. Oncotarget. 8(49). 86066–86081. 10 indexed citations
16.
Jiang, Xiangli, et al.. (2017). [Clinical Advanced in Early-stage ALK-positive Non-small Cell Lung Cancer Patients].. SHILAP Revista de lepidopterología. 20(2). 124–129. 3 indexed citations
17.
Li, Kai, Jing Wang, Xinyue Wang, et al.. (2017). Level of activated circulating endothelial cells to predict progression-free survival of Anlotinib treatment in patients with NSCLC: Analysis on ALTER-0303 study.. Journal of Clinical Oncology. 35(15_suppl). e20530–e20530. 1 indexed citations
18.
Wei, Feng, Fan Yang, Xiangli Jiang, Wenwen Yu, & Xiubao Ren. (2015). High-mobility group nucleosome-binding protein 1 is a novel clinical biomarker in non-small cell lung cancer. Tumor Biology. 36(12). 9405–9410. 13 indexed citations
19.
Jiang, Xiangli, et al.. (2014). Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes. Tumor Biology. 36(2). 861–869. 7 indexed citations
20.
Jiang, Xiangli, Qian Sun, Hui Li, Kai Li, & Xiubao Ren. (2013). The role of phosphoglycerate mutase 1 in tumor aerobic glycolysis and its potential therapeutic implications. International Journal of Cancer. 135(9). 1991–1996. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yang Peng Breakdown of academic impact, for papers by Jason Kirk Breakdown of academic impact, for papers by Mingyi Ju Breakdown of academic impact, for papers by Yongfeng Wu Breakdown of academic impact, for papers by Shunli Peng Breakdown of academic impact, for papers by Tzu‐Hua Chang Breakdown of academic impact, for papers by Wenkai Zhu Breakdown of academic impact, for papers by Rui Gou
Rankless by CCL
2026